GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Equity-to-Asset

Hua Medicine (HKSE:02552) Equity-to-Asset : -0.09 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Hua Medicine's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$-144.6 Mil. Hua Medicine's Total Assets for the quarter that ended in Dec. 2024 was HK$1,630.6 Mil. Therefore, Hua Medicine's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was -0.09.

The historical rank and industry rank for Hua Medicine's Equity-to-Asset or its related term are showing as below:

HKSE:02552' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.88   Med: 0.25   Max: 0.94
Current: -0.09

During the past 9 years, the highest Equity to Asset Ratio of Hua Medicine was 0.94. The lowest was -3.88. And the median was 0.25.

HKSE:02552's Equity-to-Asset is ranked worse than
91.74% of 1029 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs HKSE:02552: -0.09

Hua Medicine Equity-to-Asset Historical Data

The historical data trend for Hua Medicine's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine Equity-to-Asset Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.61 0.50 0.25 0.06 -0.09

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.18 0.06 -0.02 -0.09

Competitive Comparison of Hua Medicine's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hua Medicine's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Hua Medicine's Equity-to-Asset falls into.


;
;

Hua Medicine Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Hua Medicine's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-144.633/1630.647
=-0.09

Hua Medicine's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-144.633/1630.647
=-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hua Medicine  (HKSE:02552) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Hua Medicine Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hua Medicine Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Chen Li 2101 Beneficial owner
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Hong Jane Xingfang 2202 Interest of your spouse
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner

Hua Medicine Headlines

No Headlines